Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($1.05), $0.05 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $25.37 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c